SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Elute Intelligence Patent Reader launched

1 Sep 2020 07:00

RNS Number : 5446X
Frontier IP Group plc
01 September 2020
 

RNS REACH

AIM: FIPP

01 September 2020

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Elute Intelligence ground breaking Patent Reader launched commercially

 

 

Frontier IP, a specialist in commercialising intellectual property, notes the following announcement from portfolio company Elute Intelligence Holdings Limited ("Elute" or the "Company") that it is to launch its innovative Patent Reader product commercially.

The move follows a successful pilot with a dedicated user group comprising of members from multinationals, high-tech SMEs and professional intellectual property service providers.

Elute launched a dedicated COVID-19 Document Reader earlier this year to help scientists researching the disease find relevant documents more swiftly and easily.

Frontier IP holds a 43.5 per cent equity stake in the Company.

 

 

Elute Intelligence statement begins:

 

Elute Intelligence Holdings ground breaking Patent Reader launched commercially

01 September 2020 Elute Intelligence Holdings ("Elute" or the "Company") is to make patent searching quicker and easier with the commercial launch of a Patent Reader based on its novel software tools, which mimics the way people read, to intelligently search and compare unstructured text-based information.

The move follows a successful pilot with a dedicated user group comprising patent rich multi-nationals, high-tech SMEs and professional IP service providers, such as lawyers, established to support the Patent Reader's development.

The Patent Reader allows users to identify relevant patents and understand why they are relevant within minutes of starting a search. Initially, they will be able to search from more than 70 million patents in major jurisdictions, including the United States, China, the European Union and worldwide.

It is one of many potential applications for Elute's technology. The Company's software searches, compares and analyses documents to identify similarities between them by mimicking the way people read. Users are able to enter existing patents, draft applications, research papers on topics of interest and identify relevant patents. This means the approach is very different to conventional keyword or Boolean search technologies. A patent application has been filed to protect developments of the technology.

Elute was incorporated last year from an existing UK business CFL Software Limited and included complementary intellectual property developed by Frontier IP. Existing customers include the Universities and Colleges Admissions Service ("UCAS") which is using a version of the software called Copycatch to detect plagiarism in students' personal statements. Others include academic institutions, commercial researchers and lawyers.

 

Peter Fischer, Chief Executive Officer of Elute Intelligence, said: "We believe that Patent Reader has the ability to profoundly change the way patent search is carried out with huge benefits to our customers. I would like to thank the user group for its support and feedback, which has proved invaluable in allowing us to refine the product."

 Matthew White, Chief Commercialisation Officer of Frontier IP Group, said: "We are delighted with the very rapid progress being made by Elute since we started working with them last year. The Company's unique technology has a very broad range of applications. The Patent Reader is among the first products to take advantage of its immense potential."

 

 

Elute Intelligence Holdings statement ends

 

 

ENQUIRIES

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / James Hornigold

 

 

 

 

 

 

 

 

 

 

ABout frontier IP Group

Frontier IP unites science, finance and industry to build businesses based on outstanding research. It identifies strong intellectual property and accelerates its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAWPUWWRUPUGMG
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.